Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 14/20 | 0.57 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13791578 | 0.85 | CALCRL (0.60) | CALCRLMAPK10 | |
| SCHEMBL13792188 | 0.80 | CALCRL (0.86) | CALCRL | |
| SCHEMBL3891344 | 0.78 | CALCRL (0.70) | CALCRLTRPV1 | |
| SCHEMBL5097854 | 0.78 | CALCRL (0.70) | CALCRLTRPV1 | |
| SCHEMBL2213111 | 0.76 | CALCRL (0.55) | CALCRLTRPV1 | |
| SCHEMBL1894819 | 0.74 | CALCRL (0.43) | CALCRLMAPK1ROCK1 | |
| SCHEMBL1894821 | 0.74 | CALCRL (0.43) | CALCRLMAPK1ROCK1 | |
| SCHEMBL12513028 | 0.73 | CALCRL (0.46) | CALCRLTRPV1ROCK1 | |
| SCHEMBL14146297 | 0.73 | CALCRL (0.72) | CALCRL | |
| SCHEMBL13792198 | 0.72 | CALCRL (1.00) | CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470679-B2 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470679-B2 | Constrained compounds as CGRP-receptor antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-20070259850-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
| US-20070259850-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259850-A1 | CONSTRAINED COMPOUNDS AS CGRP-RECEPTOR ANTAGONISTS | CALCR, BDKRB2, CALCRL | CALCRL 3/4885MAPK10 1879/4885TRPV1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.